Clinical Trial Search

Primary: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24. — 22.8; 42.4; 49.5; 46.0 Percentage of participants — p=<0.001

Primary: Young Mania Rating Scale (YMRS) — -18.8 scores on a scale

Primary: Percentage of Participants First Achieving Therapeutic Levels at 36 Hours — 20; 18 percentage of participants

Primary: Percentage of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf — 17; 36; 95; 80…

Primary: Percent Coefficient of Fat Absorption (CFA) — 85.52; 58.02 percent CFA — p=<0.0001

Primary: Percent Coefficient of Fat Absorption (CFA) of Participants Treated With High Dose EUR-1008 and Low Dose EUR-1008 — 88.87; 89.86 percent CFA — p=0.228

Primary: Pearl Index — 1.65; 1.92 Pregnancies per 100 years of exposure

Primary: Mean Blood Glucose Concentration — 145; 172 mg/dl

Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001

Primary: Notification Rate Ratio — 48.7; 30.5 notifications/100,000 persons/year — p=<0.01

Primary: Quality of Life- Mental Component Summaty (MCS) — 39.6; 37.7 units on a scale

Primary: Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 8 — 82.44; 83.18; 37.3; 28.5 Hot flashes — p=0.0177

Primary: Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIV — 52; 41; 100; 78…

Primary: Overall Response Rate (ORR) — 30 percentage of participants

Primary: Time to Progression — 123 days